• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

GARDP and DNDi sign Alliance Agreement to strengthen collaboration

21 Dec 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

The Global Antibiotic Research & Development Partnership (GARDP) and the Drugs for Neglected Diseases initiative (DNDi) signed an Alliance Agreement on 21 December, demonstrating the willingness of both organizations to strengthen their collaboration and to develop a more strategic partnership in certain areas.

Dr Bernard Pécoul, DNDi Executive Director, and Manica Balasegaram, GARDP Executive Director

GARDP and DNDi outlined their common vision through the agreement: ‘As non-profit research and development organizations focused on infectious diseases of critical public heath importance, GARDP and DNDi are driving innovation for and equitable access to lifesaving and lifechanging treatments not delivered by the current research and development ecosystem. GARDP and DNDi share a common approach to harness the best of the public, private, non-profit, academic, and philanthropic sectors through open and collaborative approaches, to develop and deliver treatments. For both organizations, know-how and capacity of regions with a high disease burden is an integral part of our global partnership model and a backbone for fostering sustainable innovation and equitable access.’

The new Alliance Agreement aims to maximize impact and value for the organizations, including pooling selected research and development and policy expertise, as well as working together on joint projects in countries such as India and South Africa.

GARDP was launched in 2016 by the World Health Organization (WHO) and DNDi as an important element of WHO’s Global Action Plan on Antimicrobial Resistance. GARDP became a legal entity in 2019, following a successful three-year incubation, hosted by DNDi.

Partnership Antimicrobial resistance

Read, watch, share

Loading...
Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

Best science for all

Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY